SI2922875T1 - Protitelesa anti-CEACAM5 in njihove uporabe - Google Patents

Protitelesa anti-CEACAM5 in njihove uporabe

Info

Publication number
SI2922875T1
SI2922875T1 SI201330653A SI201330653A SI2922875T1 SI 2922875 T1 SI2922875 T1 SI 2922875T1 SI 201330653 A SI201330653 A SI 201330653A SI 201330653 A SI201330653 A SI 201330653A SI 2922875 T1 SI2922875 T1 SI 2922875T1
Authority
SI
Slovenia
Prior art keywords
ceacam5 antibodies
ceacam5
antibodies
Prior art date
Application number
SI201330653A
Other languages
English (en)
Slovenian (sl)
Inventor
Pierre-Francois Berne
Francis Blanche
Herve Bouchard
Beatrice Cameron
Tarik Dabdoubi
Stephanie Decary
Paul Ferrari
Alexey Rak
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of SI2922875T1 publication Critical patent/SI2922875T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201330653A 2012-11-20 2013-11-20 Protitelesa anti-CEACAM5 in njihove uporabe SI2922875T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306444 2012-11-20
PCT/EP2013/074291 WO2014079886A1 (en) 2012-11-20 2013-11-20 Anti-ceacam5 antibodies and uses thereof
EP13794894.9A EP2922875B1 (en) 2012-11-20 2013-11-20 Anti-ceacam5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SI2922875T1 true SI2922875T1 (sl) 2017-06-30

Family

ID=47257727

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331696T SI3199552T1 (sl) 2012-11-20 2013-11-20 Protitelesa proti-CEACAM5 in njihove uporabe
SI201330653A SI2922875T1 (sl) 2012-11-20 2013-11-20 Protitelesa anti-CEACAM5 in njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201331696T SI3199552T1 (sl) 2012-11-20 2013-11-20 Protitelesa proti-CEACAM5 in njihove uporabe

Country Status (38)

Country Link
US (4) US9617345B2 (enExample)
EP (3) EP3594243A1 (enExample)
JP (1) JP6324399B2 (enExample)
KR (4) KR102194748B1 (enExample)
CN (2) CN109180815B (enExample)
AR (1) AR093557A1 (enExample)
AU (2) AU2013349733C1 (enExample)
BR (1) BR112015010993B1 (enExample)
CA (2) CA3207769A1 (enExample)
CL (1) CL2015001321A1 (enExample)
CR (1) CR20150258A (enExample)
CY (1) CY1119219T1 (enExample)
DK (2) DK3199552T3 (enExample)
DO (1) DOP2015000110A (enExample)
EA (1) EA039377B1 (enExample)
EC (1) ECSP15025845A (enExample)
ES (2) ES2625742T3 (enExample)
HR (2) HRP20170743T1 (enExample)
HU (1) HUE033369T2 (enExample)
IL (1) IL238559B (enExample)
LT (2) LT3199552T (enExample)
MA (1) MA38194B1 (enExample)
MX (1) MX358321B (enExample)
MY (1) MY171100A (enExample)
NZ (1) NZ708528A (enExample)
PE (1) PE20151180A1 (enExample)
PH (1) PH12015501092B1 (enExample)
PL (2) PL2922875T3 (enExample)
PT (2) PT2922875T (enExample)
RS (2) RS55987B1 (enExample)
SG (1) SG11201503285TA (enExample)
SI (2) SI3199552T1 (enExample)
TN (1) TN2015000177A1 (enExample)
TW (2) TWI664192B (enExample)
UA (1) UA120247C2 (enExample)
UY (1) UY35147A (enExample)
WO (1) WO2014079886A1 (enExample)
ZA (1) ZA201502959B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093557A1 (es) 2012-11-20 2015-06-10 Sanofi Sa Anticuerpos anti-ceacam5 y usos de estos
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
EP3523333B1 (en) * 2016-10-10 2023-12-13 Singapore Health Services Pte Ltd Anti-ceacam6 antibodies and methods of use
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN106946989B (zh) * 2017-03-02 2020-02-18 深圳市国创纳米抗体技术有限公司 抗cea抗原vhh结构域及含有其的双特异性抗体
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CA3069363A1 (en) * 2017-07-11 2019-01-17 Pfizer Inc. Immunogenic compositions comprising cea muc1 and tert
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
HRP20231280T1 (hr) 2018-03-13 2024-02-02 Zymeworks Bc Inc. Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe
JP2021521110A (ja) 2018-04-06 2021-08-26 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物及び方法
US20210236548A1 (en) * 2018-04-20 2021-08-05 The Regents Of The University Of California Treatment of prostate cancer using chimeric antigen receptors
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
EP4659757A2 (en) 2018-08-30 2025-12-10 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
CN112888445B (zh) 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
BR112021014636A2 (pt) 2019-02-07 2021-12-21 Sanofi Sa Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3958896A1 (en) * 2019-04-23 2022-03-02 Sanofi Stable, low-viscosity antibody formulations and uses thereof
JP2022535553A (ja) * 2019-06-04 2022-08-09 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｅａｃａｍ５モノクローナル抗体、その作製方法およびその使用
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
TW202112752A (zh) 2019-06-13 2021-04-01 美商博特生物治療公司 胺基苯并氮呯化合物、免疫接合物及其用途
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
CN114630684A (zh) 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 氨基喹啉化合物、免疫缀合物及其用途
CN114786776A (zh) 2019-09-18 2022-07-22 拉姆卡普生物阿尔法股份公司 针对ceacam5和cd3的双特异性抗体
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN115362169A (zh) 2020-02-11 2022-11-18 Hcw生物科技公司 色谱树脂以及其用途
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
CA3181005A1 (en) * 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
CN115427083A (zh) * 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
CN115484989A (zh) * 2020-04-24 2022-12-16 赛诺菲 含有抗ceacam5抗体缀合物、曲氟尿苷和三氟尿嘧啶的抗肿瘤组合
US20230087871A1 (en) * 2020-04-24 2023-03-23 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
CN113201070B (zh) * 2020-08-04 2022-04-01 中山大学附属第五医院 抗ceacam5纳米抗体
CA3186059A1 (en) 2020-08-13 2022-02-17 Romas Kudirka Pyrazoloazepine immunoconjugates, and uses thereof
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
AU2021329371A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2022048883A1 (en) * 2020-09-04 2022-03-10 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4243875A1 (en) * 2020-11-10 2023-09-20 Sanofi Ceacam5 antibody-drug conjugate formulation
WO2022116079A1 (zh) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 一种抗ceacam5的人源化抗体及其制备方法和用途
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
WO2022140116A1 (en) 2020-12-21 2022-06-30 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
AU2022233150A1 (en) * 2021-03-08 2023-09-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO CD66e POLYPEPTIDES
US20240299569A1 (en) 2021-03-26 2024-09-12 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
US20240197899A1 (en) 2021-03-26 2024-06-20 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
EP4341299A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-cea antibodies and methods of use
JP2024536382A (ja) 2021-10-07 2024-10-04 サノフイ イミダゾ［４，５－ｃ］キノリン－４－アミン化合物及びそのコンジュゲート、それらの調製並びにそれらの治療用途
EP4426736A1 (en) 2021-11-05 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023081818A1 (en) * 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
KR20240112922A (ko) 2021-12-02 2024-07-19 사노피 Ceacam5 adc - 항-pd1/pd-l1 병용 요법
MX2024006766A (es) 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
WO2023164610A2 (en) * 2022-02-25 2023-08-31 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2b antibodies
JP2025508939A (ja) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
AR128745A1 (es) * 2022-03-09 2024-06-12 Merck Patent Gmbh Anticuerpos y conjugados anti-ceacam5 y usos de los mismos
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
EP4569002A2 (en) 2022-08-10 2025-06-18 Merck Sharp & Dohme LLC Proteins binding nkg2d, cd16, and ceacam5
WO2024140905A1 (en) * 2022-12-28 2024-07-04 Full-Life Technologies Hk Limited Antibodies specifically binding to ceacam5
CN120813387A (zh) 2023-03-01 2025-10-17 赛诺菲 抗ceacam5免疫缀合物用于治疗表达ceacam5的神经内分泌癌症的用途
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
TW202513094A (zh) 2023-06-05 2025-04-01 法商賽諾菲公司 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
WO2024250925A1 (en) * 2023-06-05 2024-12-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-ceacam5 antibodies
WO2025031923A1 (en) 2023-08-04 2025-02-13 Sanofi Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
CN119978136A (zh) * 2023-11-10 2025-05-13 信达生物制药(苏州)有限公司 抗dr5和ceacam5的双特异性抗体及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025184208A1 (en) * 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US144A (en) 1837-03-11 Improvement in scythe-snaths
US835A (en) 1838-07-12 X i i i x
US244A (en) 1837-06-30 Edward flint
US417A (en) 1837-09-28 Endless-ghain horse-power for driving iviaci-iii
US4640A (en) 1846-07-14 Book-lock
US4670A (en) 1846-07-28 Improvement in fish-hooks
US192A (en) 1837-05-15 Machine for cutting
US4496A (en) 1846-05-02 Machinery for
US4301A (en) 1845-12-11 Ebenezbr barrows
US4791A (en) 1846-10-03 john g
US5204A (en) 1847-07-24 james cantelo
US689A (en) 1838-04-13 Julius austin
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0971952A2 (en) 1997-04-10 2000-01-19 Royal Netherlands Academy of Arts and Sciences Diagnosis method and reagents
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6913748B2 (en) 2002-08-16 2005-07-05 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
ZA200805400B (en) 2005-12-21 2009-09-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
JP5469600B2 (ja) * 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
RU2503687C2 (ru) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Сшивающие реагенты и их применение
EP3009455A1 (en) * 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
RS56793B1 (sr) * 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
AR093557A1 (es) 2012-11-20 2015-06-10 Sanofi Sa Anticuerpos anti-ceacam5 y usos de estos
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN104948958A (zh) * 2015-07-01 2015-09-30 上海顿格电子贸易有限公司 一种利用热敏电阻限流的led灯
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
BR112021014636A2 (pt) * 2019-02-07 2021-12-21 Sanofi Sa Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
CN115484989A (zh) * 2020-04-24 2022-12-16 赛诺菲 含有抗ceacam5抗体缀合物、曲氟尿苷和三氟尿嘧啶的抗肿瘤组合
CN115427083A (zh) * 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
US20230087871A1 (en) * 2020-04-24 2023-03-23 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
EP4243875A1 (en) * 2020-11-10 2023-09-20 Sanofi Ceacam5 antibody-drug conjugate formulation
MX2024006766A (es) * 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
TW202435917A (zh) * 2022-11-17 2024-09-16 美商西雅圖遺傳學公司 Ceacam5抗體-藥物接合物及其使用方法

Also Published As

Publication number Publication date
HK1215444A1 (en) 2016-08-26
CY1119219T1 (el) 2018-02-14
US20180022817A1 (en) 2018-01-25
ZA201502959B (en) 2016-01-27
PH12015501092B1 (en) 2019-01-11
AU2018267636A1 (en) 2018-12-13
US20200102401A1 (en) 2020-04-02
KR20220084193A (ko) 2022-06-21
CN109180815B (zh) 2022-06-21
EA039377B1 (ru) 2022-01-20
NZ708528A (en) 2020-07-31
UY35147A (es) 2014-06-30
EP3594243A1 (en) 2020-01-15
BR112015010993B1 (pt) 2022-08-30
LT2922875T (lt) 2017-06-12
CA2889962A1 (en) 2014-05-30
JP2016506370A (ja) 2016-03-03
US11332542B2 (en) 2022-05-17
CR20150258A (es) 2015-06-11
LT3199552T (lt) 2020-04-10
IL238559B (en) 2018-10-31
KR20240063172A (ko) 2024-05-09
CL2015001321A1 (es) 2015-07-17
CA2889962C (en) 2023-10-24
US20160108131A1 (en) 2016-04-21
TN2015000177A1 (en) 2016-10-03
ES2625742T3 (es) 2017-07-20
EA201590986A1 (ru) 2016-05-31
TW201940519A (zh) 2019-10-16
HUE033369T2 (en) 2017-11-28
PT3199552T (pt) 2020-03-25
TW201427997A (zh) 2014-07-16
US10457739B2 (en) 2019-10-29
EP3199552B1 (en) 2019-12-25
PH12015501092A1 (en) 2015-07-27
KR102194748B1 (ko) 2020-12-23
JP6324399B2 (ja) 2018-05-16
CA3207769A1 (en) 2014-05-30
BR112015010993A2 (enExample) 2017-08-22
CN104918958B (zh) 2019-12-10
TWI664192B (zh) 2019-07-01
AU2013349733A1 (en) 2015-06-11
EP3199552A1 (en) 2017-08-02
MX2015006374A (es) 2015-10-09
PL3199552T3 (pl) 2020-06-01
CN109180815A (zh) 2019-01-11
HRP20170743T1 (hr) 2017-07-28
CN104918958A (zh) 2015-09-16
DK2922875T3 (en) 2017-06-06
US20220340682A1 (en) 2022-10-27
US9617345B2 (en) 2017-04-11
MX358321B (es) 2018-08-14
DOP2015000110A (es) 2015-08-16
PE20151180A1 (es) 2015-08-12
AU2013349733B2 (en) 2018-08-23
SI3199552T1 (sl) 2020-06-30
KR20200143527A (ko) 2020-12-23
DK3199552T3 (da) 2020-03-30
MY171100A (en) 2019-09-25
UA120247C2 (uk) 2019-11-11
ECSP15025845A (es) 2016-01-29
KR102661801B1 (ko) 2024-04-26
IL238559A0 (en) 2015-06-30
EP2922875A1 (en) 2015-09-30
EP2922875B1 (en) 2017-03-15
KR102408660B1 (ko) 2022-06-15
RS55987B1 (sr) 2017-09-29
ES2778823T3 (es) 2020-08-12
MA38194A1 (fr) 2018-02-28
MA38194B1 (fr) 2018-12-31
AR093557A1 (es) 2015-06-10
PL2922875T3 (pl) 2017-08-31
PT2922875T (pt) 2017-05-31
SG11201503285TA (en) 2015-05-28
RS60043B1 (sr) 2020-04-30
KR20150085828A (ko) 2015-07-24
AU2013349733C1 (en) 2020-10-01
HRP20200415T1 (hr) 2020-06-26
WO2014079886A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IL238559B (en) Antibodies against ceacam5 and their use
ZA201500457B (en) Anti-kit antibodies and uses thereof
EP2832856A4 (en) ANTI-LAMP5 ANTIBODIES AND USE THEREOF
IL254416A0 (en) Anti-asic1 antibodies and their uses
ZA201407927B (en) Anti-egfr antibodies and uses thereof
IL234719A0 (en) Anti-pmel17 antibodies and immunoconjugates
SG11201407099WA (en) Anti-pcsk9 antibodies and use thereof
EP2879708A4 (en) ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
SG11201405881TA (en) Anti-lgr5 antibodies and immunoconjugates
HUE037613T2 (hu) Anti-TLR4 antitestek és azok felhasználása
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP2879711A4 (en) ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
GB201208372D0 (en) Antibodies and uses thereof
GB201202021D0 (en) Co-sleeper and breastfeeder